Fractyl Health (GUTS) vs LeonaBio (LONA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
LeonaBio (LONA) has outperformed Fractyl Health (GUTS) over the past year, gaining 45.9% versus a loss of 74.8%. Fractyl Health is the larger company by market cap ($58.6 million vs $54.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GUTS | LONA |
|---|---|---|
| Share price | $4.42 | $5.75 |
| Market cap | $58.63M | $54.13M |
| 1-day change | +4.49% | -0.09% |
| YTD return | -83.98% | -24.04% |
| 1-year return | -74.82% | +45.94% |
| 5-year return | — | -93.99% |
| EPS (TTM) | $-10.56 | $-23.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $29.34 | $14.21 |
| 52-week low | $4.14 | $2.21 |
| Distance from 52-week high | -84.94% | -59.57% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +1266.52% | +201.65% |
| Average volume | 156.16K | 185.45K |
| Shares outstanding | 13.26M | 9.42M |
| Employees | 100 | 19 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LONA has outperformed GUTS by 120.8 percentage points over the past year.
About Fractyl Health
GUTS stock →Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. It develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.
Health Care · Medical/Dental Instruments · 100 employees
About LeonaBio
LONA stock →LeonaBio, Inc., clinical-stage biopharmaceutical company, engages in the development of novel therapeutics for high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis. The company's lead products include lasofoxifene and ATH-1105, a novel small molecule therapies with the potential to address devastating diseases where current treatment options are limited or ineffective.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 19 employees
GUTS vs LONA FAQ
Which is bigger, Fractyl Health or LeonaBio?
Fractyl Health (GUTS) is larger, with a market capitalization of $58.63M compared with $54.13M for LeonaBio (LONA).
Which stock has performed better over the past year, GUTS or LONA?
LONA returned +45.94% over the past 12 months, compared with -74.82% for GUTS (price return, excluding dividends). Past performance does not predict future results.
Are Fractyl Health and LeonaBio in the same industry?
Both are in the Health Care sector, but in different industries: Medical/Dental Instruments for Fractyl Health and Biotechnology: Biological Products (No Diagnostic Substances) for LeonaBio.